ISIN | LU1176837026 |
---|---|
Valor Number | 26967179 |
Bloomberg Global ID | |
Fund Name | PROTEA - Sectoral Biotech Opportunities Fund IF EUR |
Fund Provider |
Sectoral Asset Management Inc
1010 Sherbrooke St. West, Suite 1610 QC H3A 2R7 Montreal Canada Phone: +1 514 849 8777 E-Mail: BusinessDevelopment@sectoral.com |
Fund Provider | Sectoral Asset Management Inc |
Representative in Switzerland |
FundPartner Solutions (Suisse) SA Genève 75 |
Distributor(s) | |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel) |
Redemption Condition | The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel) |
Investment Strategy *** | This Sub-Fund aims to achieve capital growth in USD. While respecting the principle of risk diversification, the Sub-Fund’s assets are primarily invested in equities, equity-like transferable securities, participation certificates etc. issued by particularly innovative small, mid and large cap biotech companies worldwide which are active in the human medicine sector and depositary receipts, such as American Depositary Receipts (ADRs), Global Depositary Receipts (GDRs) and European Depositary Receipts (EDRs), referring to such securities. While no geographical restrictions apply re. specific countries or regions, the industry and therefore the Sub-Fund’s investments are centered in North America and Western Europe. |
Peculiarities |
Current Price * | 10.21 EUR | 04.11.2024 |
---|---|---|
Previous Price * | 10.16 EUR | 31.10.2024 |
52 Week High * | 10.63 EUR | 16.07.2024 |
52 Week Low * | 8.49 EUR | 28.11.2023 |
NAV * | 10.21 EUR | 04.11.2024 |
Issue Price * | 10.21 EUR | 04.11.2024 |
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 24,348,577 | |
Unit/Share Assets *** | 2,232,674 | |
Trading Information SIX |
YTD Performance | +4.08% |
29.12.2023 - 04.11.2024
29.12.2023 04.11.2024 |
---|---|---|
YTD Performance (in CHF) | +5.38% |
29.12.2023 - 04.11.2024
29.12.2023 04.11.2024 |
1 month | +0.10% |
04.10.2024 - 04.11.2024
04.10.2024 04.11.2024 |
3 months | +2.61% |
05.08.2024 - 04.11.2024
05.08.2024 04.11.2024 |
6 months | +5.58% |
06.05.2024 - 04.11.2024
06.05.2024 04.11.2024 |
1 year | +14.46% |
06.11.2023 - 04.11.2024
06.11.2023 04.11.2024 |
2 years | +0.39% |
04.11.2022 - 04.11.2024
04.11.2022 04.11.2024 |
3 years | -12.21% |
04.11.2021 - 04.11.2024
04.11.2021 04.11.2024 |
5 years | +29.08% |
04.11.2019 - 04.11.2024
04.11.2019 04.11.2024 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Gilead Sciences Inc | 9.90% | |
---|---|---|
Regeneron Pharmaceuticals Inc | 8.57% | |
Amgen Inc | 6.33% | |
Vertex Pharmaceuticals Inc | 6.24% | |
AstraZeneca PLC ADR | 4.63% | |
Alnylam Pharmaceuticals Inc | 4.07% | |
Biogen Inc | 3.26% | |
argenx SE ADR | 2.90% | |
Moderna Inc | 2.60% | |
Biomarin Pharmaceutical Inc | 2.43% | |
Last data update | 30.09.2024 |
TER | 1.39% |
---|---|
TER date | 30.06.2023 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 1.10% |
Ongoing Charges *** | 1.38% |
SRRI ***
|
|
SRRI date *** | 30.09.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |